Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: A Pediatric Oncology Group randomized phase II study

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1521-1525

  Steuber, C P ^a   Krischer, J ^a   Holbrook, T ^a   Camitta, B ^a   Land, V ^a   Sexauer, C ^a   Mahoney, D ^a   Weinstein, H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; AZACITIDINE; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; INFECTION; LIVER TOXICITY; MALE; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0029963320     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1521     Document Type: Article

References (34)

1. Steuber CP, Civin C, Krischer J, et al: A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: Results of a Pediatric Oncology Group study. J Clin Oncol 9:247-258, 1991
2. Ravindranath Y, Steuber CP, Krischer J, et al: High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: A Pediatric Oncology Group study. J Clin Oncol 9:572-580, 1991
3. Woods W, Ruyman FB, Lampkin B, et al: The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. Cancer 66:1106-1113, 1990
4. Creutzig U, Ritter J, Riehm H, et al: The childhood AML studies BFM-78 and BFM-83: Treatment results and risk factor analysis. Haematol Blood Transfus 30:71-75, 1987
5. Wells RJ, Woods WG, Buckley JD, et al: Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: A Childrens Cancer Group study. J Clin Oncol 12:2367-2377, 1994
6. Hurwitz CA, Mounce KG, Grier HE: Treatment of patients with acute myelogenous leukemia: Review of clinical trials of the past decade. J Pediatr Hematol Oncol 17:185-197, 1995
7. Chard RL, Krivit W, Bleyer A et al: Phase II study of VP-16-213 in childhood malignant disease: Children's Cancer Study Group Report. Cancer Treat Rep 63:1755-1759, 1979
8. Rozenweig M, Von Hoff DD, Henney JE, et al: VM-26 and VP-16-213: A comparative analysis. Cancer 40:334-342, 1977
9. Rivera G, Avery T and Pratt C: 4′-Dimethylepipodophyllotoxin 9-(4,6-0,2-thenylidene-β-glucopyanoside [NSC 122819]; VM-26) and 4′Dimethylepipodophyllotoxin 9-(4,6-0,ethylidene-β-D-glucopyranoside [NSC-141540]; VP-16-213) in childhood cancer: Preliminary observations. Cancer Chemother Rep 59:743-749, 1975
10. Louie AC, Issell BF: Amsacrine (AMSA) - A clinical review. J Clin Oncol 3:562-592, 1985
11. Krischer J, Land V, Civin C, et al: Evaluation of AMSA in children with acute leukemia: A Pediatric Oncology Group study. Cancer 54:207-210, 1984
12. Karon M, Sieger L, Leimbrock S, et al: 5-azacytidine: A new active agent for the treatment of acute leukemia. Blood 42:359-365, 1973
13. Bishop JF: Etoposide in the treatment of leukemias. Semin Oncol 19:33-38, 1992
14. Vogler WR, Miller DS, Keller JW: 5-azacytidine (NSC 102816): A new drug for the treatment of myeloblastic leukemia. Blood 48:331-337, 1976
15. Von Hoff DD, Slavik M and Muggia FM: 5-azacytidine; A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med 85:237-245, 1976
16. Hakami N, Look AT, Steuber, CP, et al: Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 5:1022-1025, 1987
17. Steuber CP, Holbrook T, Camilla B, et al: Toxicity trials of amsacrine (AMSA) and etoposide +/- azacilidine (AZ) in childhood acute nonlymphocytic leukemia (ANLL): A pilot study. Invest New Drugs 9:181-184, 1991
18. Steuber P, Holbrook T, Camilla B, et al: Induction treatment of refractory or recurrent childhood AML using amsacrine and etoposide with or without 5-azacytidine: A phase II Pediatric Oncology Group study. Proc Am Soc Clin Oncol 13:A1044, 1994 (abstr)
19. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukemias: French-American-British Cooperative Group. Br J Haematol 33:451-458, 1976
20. Miller AB, Hoogstraten B, Stoquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
21. Shuster JJ: EXACTB and Conf: Exact unconditional procedures for binomial data. Am Statist 42:234, 1988
22. Ravindranath Y, Yeager A, Krischer J, et al: Intensive consolidation chemotherapy (ICC) vs purged autologous bone marrow transplantation (ABMT) early in remission for treatment of childhood acute myeloid leukemia (AML): Preliminary results of Pediatric Oncology Group (POG) study 8821. Proc Am Soc Clin Oncol 13:A1053, 1994 (abstr)
23. Mayer RJ: Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Oncol 14:384-396, 1987
24. Lampkin B, Masterson M, Sambrano J, et al: Current chemotherapeutic treatment strategies in childhood acute nonlymphocytic leukemia. Semin Oncol 14:397-406, 1987
25. Weinstein HJ, Mayer RJ, Rosenthal DS, et al: Acute myelogenous leukemia in children and adults: VAPA update. Blood 62:315-319, 1983
26. Wells RJ, Arndt CAS: New agents for treatment of children with acute myelogenous leukemia. J Pediatr Hematol Oncol 17:225-233, 1995
27. Dahl G, Kalwinsky D, Mirro J, et al: Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission. J Clin Oncol 8:295-303, 1990
28. Hurd D: Allogeneic and autologous bone marrow transplantation for acute nonlymphocytic leukemia. Semin Oncol 14:407-416, 1987
29. Champlin R, Gale RP: Bone marrow transplantation for acute leukemia: Recent advances and comparison with alternative therapies. Semin Hematol 24:55-67, 1987
30. Dinndorf P, Bunin N: Bone marrow transplantation for children with acute myelogenous leukemia. J Pediatric Hematol Oncol 17:211-224, 1995
31. Kahn SB, Sklaroff R, Lebedda J, et al: 4′-(9-acrindinylamino) methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia. J Clin Oncol 6:493-502, 1983
32. Look AT, Dahl GV, Kalwinsky D, et al: Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine. Cancer Treat Rep 65:995-999, 1981
33. Worsley AM, Catovsky D, Goldman JM, et al: New combination chemotherapy for relapsed acute myeloid leukemia. Lancet 2:1232, 1984
34. Arlin ZA, Feldman EJ, Mittelman A, et al: Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer 68:1198-1200, 1991